LON:SHP Shire (SHP) Share Price, News & Analysis → The #1 Crypto for AI (From Weiss Ratings) (Ad) Free SHP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume51,588 shsAverage Volume3.14 million shsMarket Capitalization£42.73 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Shire alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Shire Stock (LON:SHP)Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.Read More Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. SHP Stock News HeadlinesApril 5, 2024 | morningstar.comSouth Harz Potash Ltd SHPOctober 20, 2022 | bbc.comWhy the capture of Shire is so important for Ethiopia - BBCMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 17, 2022 | reuters.comEthiopian army captures large city from Tigray forces: sources - ReutersOctober 16, 2022 | barrons.comAU Calls On Ethiopia Rivals To 'Recommit' To Peace - Barron'sOctober 12, 2022 | news.yahoo.comShire Chic? This $30 Million Mountaintop Lodge in North Carolina Comes With a Hobbit-Style Guest House - Yahoo NewsOctober 11, 2022 | nypost.comLoose lips lead to lawsuits over allegations from 'The Godfather' set - New York Post October 11, 2022 | yahoo.comShire Chic? This $30 Million Mountaintop Lodge in North Carolina Comes With a Hobbit-Style Guest House - Yahoo LifeMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 9, 2022 | uk.news.yahoo.comDeputy Mayor and Thwaites Horse Shire team open new kitchen facility - Yahoo News UKOctober 7, 2022 | forbes.comKansas City Chiefs Linemen Creed Humphrey And Trey Smith Use T-Shirts To Build Brand - ForbesOctober 7, 2022 | cnn.comKanye West tells Tucker Carlson he thought 'White Lives Matter' shirt was 'funny' - CNNOctober 1, 2022 | mirror.co.ukThe Queen's 'special' grey shire horses pay their respects with final act of service - The MirrorSeptember 30, 2022 | dailymail.co.ukJANE FRYER: Queen's 'special' grey shire horses 'pay their respects' to the late monarch - Daily MailSeptember 30, 2022 | startribune.comWitnesses: Airstrike in Ethiopia's Tigray kills civilians - Star TribuneSeptember 30, 2022 | abcnews.go.comWitnesses: Airstrike in Ethiopia's Tigray kills civilians - ABC NewsSeptember 27, 2022 | forbes.com2023 Bentley Bentayga EWB First Drive: A Thoroughbred Among Shire Horses - ForbesSeptember 26, 2022 | uk.news.yahoo.comTwo Shire horses take Queen’s flowers away for composting - Yahoo News UKSeptember 7, 2022 | npr.orgSinger-songwriter Amanda Shires reflects on marriage on 'Take it Like a Man' - NPRSeptember 5, 2022 | npr.orgPeeling back the layers of Amanda Shires' life and musical career : World Cafe Words and Music Podcast - NPRAugust 7, 2022 | bbc.comCouncil makes money-saving move closer to city centre - BBCAugust 3, 2022 | news.yahoo.com'I'm gonna do me': Amanda Shires on women in country music and her new album 'Take It Like a Man' - Yahoo NewsJuly 31, 2022 | npr.orgAmanda Shires talks new album 'Take It Like A Man' - NPRJuly 31, 2022 | theguardian.comFrom WAG Nation to The Shire: the 15 Australian reality shows we all forgot about – sorted - The GuardianJuly 18, 2022 | bbc.comStafford business centre opens in town's historic Shire Hall - BBCJuly 9, 2022 | bbc.comCambridgeshire council officially opens Alconbury HQ - BBCJuly 7, 2022 | dailymail.co.ukBass Coast Shire Council announces cat ban and fines to protect Phillip Island penguins - Daily MailSee More Headlines Receive SHP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:SHP CUSIPN/A CIKN/A Webwww.shire.com Phone+353-1-6096000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares910,982,976Free FloatN/AMarket Cap£42.73 billion OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Flemming Ornskov M.P.H. (Age 60)MBA, M.D., MPH, CEO, MD & Exec. Director Mr. Thomas J. W. Dittrich (Age 54)CFO & Director Gisele DionChief Accounting OfficerMr. Matthew Walker (Age 54)Head of Technical Operations Dr. Andreas Busch Ph.D. (Age 55)Head of R&D and Chief Scientific Officer Key CompetitorsHaleonLON:HLNGSKLON:GSKBTGLON:BTGAbcamLON:ABCGenusLON:GNSView All Competitors Should I Buy Shire Stock? SHP Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Shire plc: Shire plc offers a diverse portfolio of products targeting rare diseases and specialized conditions, providing a unique market niche with potentially high demand and limited competition. The company has a strong track record of research, development, and successful commercialization of innovative medicines, indicating a potential for continued growth and profitability. Recent collaborations and licensing agreements with reputable companies like Pfizer Inc. and Ipsen Bioscience Inc. suggest promising future developments and expansion opportunities. Shire plc's focus on therapeutic areas such as hematology, genetic diseases, and neuroscience aligns with growing healthcare trends and increasing global healthcare expenditure, potentially leading to sustained revenue growth. Current stock price of Shire plc reflects a favorable valuation compared to its industry peers, presenting a potentially attractive entry point for investors seeking undervalued opportunities. Cons Investors should be bearish about investing in Shire plc for these reasons: Regulatory challenges and uncertainties in the biotechnology industry could impact Shire plc's product development timelines and market approvals, leading to potential delays and revenue setbacks. Intense competition in the biopharmaceutical sector may pose risks to Shire plc's market share and pricing power, affecting its profitability and growth prospects. Fluctuations in foreign exchange rates and geopolitical factors could expose Shire plc to currency risks and operational disruptions in its global operations, potentially impacting financial performance. Dependency on a few key products for a significant portion of revenue exposes Shire plc to concentration risk, where any adverse events or competition could have a disproportionate impact on overall financial results. Market volatility and macroeconomic factors could influence investor sentiment towards biotechnology stocks, leading to potential price fluctuations in Shire plc's shares despite its fundamental strengths. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 11, 2024. Please send any questions or comments about these Shire pros and cons to contact@marketbeat.com. SHP Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Shire own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Barclays (BARC), Centrica (CNA), Erie Indemnity (ERIE), Lloyds Banking Group (LLOY), GSK (GSK), International Consolidated Airlines Group (IAG), Vodafone Group Public (VOD), Prudential (PRU), Shire (SHPG) and Randgold Resources (RRS). This page (LON:SHP) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shire plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.